My watch list
my.chemeurope.com  

my.chemeurope.com

With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.

  • My watch list
  • My saved searches
  • My saved topics
  • My newsletter
Register free of charge
Login  
eng  
DeutschEnglishFrançaisEspañol

Rizatriptan



Rizatriptan
Systematic (IUPAC) name
N,N-dimethyl-2- [5-(1,2,4-triazol-1-ylmethyl)- 1H-indol-3-yl]ethanamine
Identifiers
CAS number 145202-66-0
ATC code N02CC04
PubChem 5078
DrugBank APRD00008
Chemical data
Formula C15H19N5 
Mol. mass 269.345 g/mol
Pharmacokinetic data
Bioavailability 45%
Protein binding 14%
Metabolism by monoamine oxidase
Half life 2–3 hours
Excretion 82% urine; 12% feces
Therapeutic considerations
Pregnancy cat.

C

Legal status
Routes Oral

Rizatriptan (Maxalt®) is a triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in the United States and Canada. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom.

This medication is used to treat acute migraine attacks. It does not prevent future migraine attacks.

Indicated for:

  • migraine headache with or without aura

Contraindications:

Side effects:

Severe:

  • coronary artery vasospasm
  • transient myocardial ischemia
  • myocardial infarction
  • ventricular tachycardia
  • ventricular fibrillation
  • hypertensive crisis

Atypical sensations:

  • paresthesia

Cardiovascular:

  • palpitations
  • syncope
  • hypertension
  • hypotension

Ear, nose, and throat:

  • tinnitus
  • sensitivity to noise
  • sinusitis
  • allergic rhinitis
  • upper respiratory inflammation

Gastrointestinal:

  • diarrhea

Muscular:

  • myalgia

Neurological:

  • phonophobia
  • photophobia

Respiratory:

  • dyspnea

Skin:

  • sweating

Miscellaneous:

  • hypersensitivity
v • d • e
Antimigraine preparations (N02C)
Ergot alkaloidsDihydroergotamine • Ergotamine • Methysergide • Lisuride
Corticosteroid derivativesFlumedroxone
Selective serotonin (5-HT1) agonistsTriptans (Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan)
Other antimigraine preparationsPizotifen • Clonidine • Iprazochrome • Dimetotiazine • Oxetorone
v • d • e
Tryptamines

4-Acetoxy-DET • 4-Acetoxy-DIPT • 4-Acetoxy-DMT • 4-HO-DIPT • 5-Bromo-DMT • 5-Fluoro-α-MT • 5-MeO-α-ET  • 5-MeO-α-MT • 5-MeO-DALT • 5-MeO-DET • 5-MeO-DIPT • 5-MeO-DMT • 5-MeO-DPT • 5-MeO-MIPT • α-ET • α-MT • Baeocystin • Bufotenin • DET • DiPT • DMT • DPT • Ethocybin • EiPT • Ethocin • Ibogaine • Iprocin • MET • MiPT • Miprocin • Melatonin • NMT • Norbaeocystin • Normelatonin • PiPT • Psilocin • Psilocybin • Rizatriptan • Serotonin • Sumatriptan • Tryptamine • Tryptophan

v • d • e
Merck & Co., Inc.
Corporate Directors:Richard Clark · Johnnetta Cole · William Harrison · William Kelley · Rochelle Lazarus · Thomas Shenk · Anne Tatlock · Samuel Thier · Wendell Weeks · Peter Wendell
Products:Indinavir · Aprepitant · Alendronate · Rizatriptan · Finasteride · Losartan · Lovastatin · Montelukast · Rofecoxib · Ezetimibe/simvastatin · Ezetimibe · Raltegravir · Simvastatin · Sitagliptin · Vorinostat · The Merck Index · The Merck Manual
Annual Revenue: $22.9 billion USD (2% FY 2004) · Employees: 63,000 · Stock Symbol: NYSE: MRK · Website: www.merck.com
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rizatriptan". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE